Transenteric delivery of incretin triagonist GLP-1 ... an oral GLP-1/GLP-2 dual agonist for the treatment of obesity, expected to initiate in 2025 - SAN JOSE, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE ...

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...

Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.

GLP-1 is in the same family of hormones as NPF -- they're both called incretins because they can increase the secretion of insulin. There has been an explosion of research on GLP-1 agonists ...

The success surrounding the medications for obesity and diabetes has sparked research into whether they could also be an ...

A previous study with this incretin triagonist delivered transenterically ... a study demonstrating oral delivery of GLP-1 receptor agonist with high bioavailability via the RaniPill capsule.

A previous study with this incretin triagonist delivered transenterically demonstrated pharmacodynamic effects comparable to subcutaneous injection. Rani also previously completed a study ...